Russell Cohen
Gastroenterology · Chicago, ILNPI 1336201888
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $456,236 of the $689,889 with a category attached, or 66.1%. 22 manufacturers reported payments, led by AbbVie at 37.3% of the total. Reporting peaked in 2022 at $183,980 and has fallen 68.1% since, to $58,624 in 2025. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 503 payments — averaging $1371.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$258K
- Takeda Pharmaceuticals U.S.A., Inc.$118K
- E.r. Squibb & Sons, L.L.C.$108K
- Pfizer$63K
- Johnson & Johnson$44K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$15K
- plus $84K from 16 others
Across 84 payments — averaging $3590.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$74K
- Pfizer$72K
- Bristol Myers Squibb$64K
- UCB Biosciences Inc.$32K
- Genentech, Inc.$29K
- Bausch Health US, LLC$18K
- plus $13K from 3 others
What the payments were for
- Consulting fees$170,72525%
- Speaking & faculty fees$456,23666%
- Travel & lodging$51,1377%
- Food & beverage$11,7842%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 199 | $257,664 |
| Takeda Pharmaceuticals U.S.A., Inc. | 90 | $118,001 |
| E.r. Squibb & Sons, L.L.C. | 75 | $107,819 |
| Pfizer | 7 | $63,279 |
| Johnson & Johnson | 46 | $44,220 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $14,979 |
| Merck | 10 | $14,407 |
| F. Hoffmann-la Roche AG | 4 | $14,276 |
| Hexal AG | 2 | $10,645 |
| Sandoz | 1 | $10,140 |
| Eli Lilly | 4 | $7,880 |
| Bristol Myers Squibb | 24 | $6,636 |
| Gilead | 2 | $5,990 |
| Organon | 2 | $3,525 |
| Janssen Scientific Affairs, LLC | 6 | $2,850 |
| Biocon Biologics Inc | 1 | $2,593 |
| Janssen Global Services, LLC | 1 | $1,860 |
| Celltrion USA Inc. | 2 | $1,834 |
| Celltrion Healthcare Co., Ltd | 1 | $550 |
| Stryker | 5 | $455 |
| Lilly USA, LLC | 2 | $161 |
| Genentech USA, Inc. | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$689,889 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 71 | $1,925,320 |
| Skyrizi On-BodyRisankizumab-Rzaa | 57 | $1,046,520 |
| Humira PenAdalimumab | 49 | $592,178 |
| Humira(Cf) PenAdalimumab | 18 | $265,559 |
| RinvoqUpadacitinib | 20 | $209,899 |
| ZeposiaOzanimod Hydrochloride | 13 | $102,208 |
| Xeljanz XrTofacitinib Citrate | 12 | $61,384 |
| PentasaMesalamine | 20 | $35,807 |
| Mesalamine | 54 | $28,742 |
| Mesalamine ErMesalamine | 12 | $9,780 |
| Balsalazide Disodium | 17 | $4,654 |
| Azathioprine | 32 | $1,948 |
| Colestipol Hcl | 29 | $1,901 |
| LoperamideLoperamide Hcl | 31 | $1,088 |
| Ciprofloxacin Hcl | 51 | $793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $44,220 | $1,925,32071 claims |
| AbbVieRinvoq | $257,664 | $209,89920 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $107,819 | $102,20813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 787 gastroenterology providers in Illinois.
Other gastroenterology in Chicago
- David RubinChicago$1.5M
- Stephen HanauerChicago$1.4M
- Steven FlammChicago$1.3M
- Darren BrennerChicago$1.1M
- Parambir DulaiChicago$668K
- Christopher ChapmanChicago$645K
- Saurabh KapurChicago$532K
- Ikuo HiranoChicago$457K
- Adam SteinChicago$438K
- John PandolfinoChicago$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.